Elimination half-life of vitamin K1 in neonates is longer than is generally assumed: implications for the prophylaxis of haemorrhaghic disease of the newborn.
Stoeckel
K
K
CLINPHARM SUPPORT, Basel, Switzerland.
Joubert
P H
PH
Grüter
J
J
D015415:Biomarkers; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006490:Hemostatics / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D011498:Protein Precursors / Q000032:analysis / Q000378:metabolism*; D011516:Prothrombin / Q000032:analysis / Q000378:metabolism*; D012044:Regression Analysis; D010837:Vitamin K 1 / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006475:Vitamin K Deficiency Bleeding / Q000517:prevention & control*
D015415:Biomarkers; D006490:Hemostatics; D011498:Protein Precursors; C008208:acarboxyprothrombin; D010837:Vitamin K 1; D011516:Prothrombin